Immunologic properties of RA27-3 rubella virus vaccine. A comparison with strains presently licensed in the United States.
D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000032:analysis; D000917:Antibody Formation; D002648:Child; D002675:Child, Preschool; D003168:Complement Fixation Tests; D005260:Female; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D007111:Immunity, Cellular; D007117:Immunization, Secondary; D007279:Injections, Subcutaneous; D008297:Male; D009500:Neutralization Tests; D009666:Nose / Q000276:immunology; D011233:Precipitin Tests; D012411:Rubella Vaccine; D012412:Rubella virus / Q000009:adverse effects / Q000276:immunology; D012737:Sex Factors; D014481:United States; D014613:Vaccines, Attenuated / Q000008:administration & dosage
D000914:Antibodies, Viral; D012411:Rubella Vaccine; D014613:Vaccines, Attenuated